Countouriotis Athena 4

What Happened
Athena Countouriotis, a director of Passage Bio, received a grant/award of 10,539 derivative shares on 2026-05-19. The Form 4 shows an acquisition at $0.00 (this is reported as a derivative award, not an open-market purchase or sale). No immediate sale or cash proceeds are reported.

Key Details

• Transaction date: 2026-05-19; Form 4 filed: 2026-05-21 (timely filing).
• Amount: 10,539 derivative shares; reported acquisition price: $0.00.
• Shares owned after transaction: not disclosed in the information provided.
• Footnote: the award is a stock option that vests in full on the earlier of (i) the one-year anniversary of the grant or (ii) the issuer’s 2027 Annual Meeting, subject to continued service.
• Transaction type: “A” (grant/award). No 10b5-1 plan or tax-withholding details disclosed.

Context
This was a compensation grant (a derivative award/stock option) to a director. Such awards typically vest over time and do not represent an immediate market buy or sell — they give the holder the right to receive or buy shares in the future if vesting/exercise conditions are met. Grants to directors are routine for board compensation and should be interpreted as part of pay, not a direct buy or sell signal.